A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.

We have explored the concept of a molecular extender arm attached to a κ opioid agonist pharmacophore 3 (ICI-199,441) in an effort to potentially interact with a complementary group on a neighboring opioid receptor. The molecular arm containing a terminal amine group was lengthened incrementally from 11 up to 18 atoms. Increasing the number of atoms in the arm produced virtually no change in the mouse intracerebroventricular (i.c.v.) antinociceptive potency. In contrast, the intrathecal (i.t.) potency of 6 (KDA-16) with a 16-atom arm was dramatically increased, as reflected by its antinociceptive i.c.v./i.t. ED50 ratio of ∼130. Further lengthening led to a decreased ED50 ratio. In vivo selective antagonist studies of KDA-16 revealed that κ and δ opioid receptors were responsible for the greatly enhanced i.t. potency. Calcium release experiments in HEK-293 cells suggested that KDA-16 selectively activate κ-δ heteromers. These data are consistent with the reported possible presence of heteromeric κ-δ opioid receptors in mouse spinal cord but not in the brain. The use of a molecular extender arm may be useful for developing spinally selective analgesics.

[1]  P. Portoghese,et al.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists. , 2010, ACS chemical neuroscience.

[2]  P. Portoghese,et al.  A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. , 2009, Bioorganic & medicinal chemistry letters.

[3]  L. Miller,et al.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. , 2009, Journal of medicinal chemistry.

[4]  P. Portoghese,et al.  Selectivity of δ- and κ-Opioid Ligands Depends on the Route of Central Administration in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[5]  David J. Daniels,et al.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  David J. Daniels,et al.  Interaction of Bivalent Ligand KDN21 with Heterodimeric δ-κ Opioid Receptors in Human Embryonic Kidney 293 Cells , 2005, Molecular Pharmacology.

[7]  Jamie Fong,et al.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Xiaochun Sun,et al.  Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer , 2005, Molecular Pharmacology.

[9]  David J. Daniels,et al.  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .

[10]  M. Wessendorf,et al.  Coexistence of kappa- and delta-opioid receptors in rat spinal cord axons , 2001, Neuroscience Letters.

[11]  L. Devi,et al.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  B. O'dowd,et al.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.

[13]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[14]  T. Blackburn,et al.  Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists. , 1991, Journal of medicinal chemistry.

[15]  P. Portoghese,et al.  Design of peptidomimetic .delta. opioid receptor antagonists using the message-address concept [Erratum to document cited in CA112(25):235659s] , 1990 .

[16]  K. Gulya,et al.  Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. , 1988, European journal of pharmacology.

[17]  A. Lipkowski,et al.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. , 1987, Life sciences.